301075 多瑞医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-12.520-8.6512.4752.65513.235
总资产报酬率 ROA (%)-5.347-4.8071.9132.34311.208
投入资产回报率 ROIC (%)-7.878-6.2932.0742.44912.454

边际利润分析
销售毛利率 (%)4.63042.41568.55276.98188.608
营业利润率 (%)-80.525-35.6416.6375.30013.860
息税前利润/营业总收入 (%)-71.537-34.3055.2953.31613.853
净利润/营业总收入 (%)-82.263-35.3355.1134.63412.436

收益指标分析
经营活动净收益/利润总额(%)97.06387.82616.70859.91786.991
价值变动净收益/利润总额(%)-1.410-6.84725.6620.054-0.268
营业外收支净额/利润总额(%)0.7510.0100.277-1.101-0.170

偿债能力分析
流动比率 (X)1.1651.2385.0244.47811.611
速动比率 (X)1.0301.1484.7674.25211.455
资产负债率 (%)55.73450.91323.37016.1827.375
带息债务/全部投入资本 (%)26.93021.29819.27812.1962.961
股东权益/带息债务 (%)223.207308.203416.939719.0753,277.070
股东权益/负债合计 (%)73.99786.592308.101516.6751,262.815
利息保障倍数 (X)-7.455-25.609-3.893-1.722836.483

营运能力分析
应收账款周转天数 (天)180.661136.61591.08884.25567.179
存货周转天数 (天)114.535102.593112.82583.04573.544